Yousif Capital Management LLC Lowers Position in Hologic, Inc. $HOLX

Yousif Capital Management LLC trimmed its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 29.1% during the third quarter, HoldingsChannel reports. The fund owned 34,800 shares of the medical equipment provider’s stock after selling 14,295 shares during the quarter. Yousif Capital Management LLC’s holdings in Hologic were worth $2,349,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in HOLX. Chung Wu Investment Group LLC purchased a new stake in Hologic in the 2nd quarter valued at approximately $26,000. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Hologic by 193.6% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 273 shares during the period. Loomis Sayles & Co. L P purchased a new stake in shares of Hologic in the second quarter valued at approximately $33,000. Cromwell Holdings LLC grew its holdings in Hologic by 307.0% during the second quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider’s stock worth $38,000 after acquiring an additional 436 shares during the period. Finally, CYBER HORNET ETFs LLC purchased a new position in Hologic in the second quarter worth $40,000. Institutional investors and hedge funds own 94.73% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. Mizuho lowered shares of Hologic from an “outperform” rating to a “neutral” rating and boosted their target price for the stock from $70.00 to $78.00 in a research report on Thursday, October 23rd. Evercore ISI set a $78.00 price objective on shares of Hologic and gave the stock an “outperform” rating in a report on Tuesday, October 7th. Leerink Partners increased their target price on shares of Hologic from $70.00 to $78.00 and gave the company a “market perform” rating in a report on Tuesday, October 21st. Wall Street Zen lowered Hologic from a “buy” rating to a “hold” rating in a research note on Wednesday, October 1st. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Hologic in a research note on Friday, October 31st. Five analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $79.29.

Insider Activity at Hologic

In related news, Director Christiana Stamoulis sold 7,402 shares of Hologic stock in a transaction dated Monday, October 20th. The stock was sold at an average price of $73.07, for a total transaction of $540,864.14. Following the completion of the sale, the director owned 47,336 shares in the company, valued at approximately $3,458,841.52. This trade represents a 13.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.88% of the stock is currently owned by insiders.

Hologic Price Performance

HOLX stock opened at $74.50 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 3.75 and a quick ratio of 3.06. The company’s 50 day simple moving average is $74.45 and its 200-day simple moving average is $69.15. Hologic, Inc. has a 12 month low of $51.90 and a 12 month high of $75.34. The firm has a market capitalization of $16.61 billion, a PE ratio of 30.04, a P/E/G ratio of 2.11 and a beta of 0.70.

Hologic (NASDAQ:HOLX) last posted its earnings results on Monday, November 3rd. The medical equipment provider reported $1.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.10 by $0.03. The firm had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.03 billion. Hologic had a return on equity of 20.13% and a net margin of 13.80%.Hologic’s revenue was up 6.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.01 EPS. Equities analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Hologic Company Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.